All lobbying filings

LEAVITT PARTNERS, LLC

Lobbying for SAVE RARE TREATMENTS TASK FORCE · Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

ROBERT CLAYTON ALSPACH

Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
JOSH TRENT

Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.